INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
The present invention relates to novel compounds that are inhibitors of post-proline aminopeptidases. The compounds are useful as antiproliferative agents and in the treatment of, inter alia, type 2 diabetes and impaired glucose tolerance.
BACKGROUND
The enzyme dipeptidyl peptidase IV, herein abbreviated DP-IV (and elsewhere as DAP-IV or DPP-IV) and also known by the classification EC.3.4.14.5, is a serine protease that cleaves the N-terminal dipeptide from peptides that begin with the sequence H-Xaa-Pro (where Xaa is any amino acid, although preferably a lipophilic one, and Pro is proline). It will also accept as substrates peptides that begin with the sequence H-Xaa-Ala (where Ala is alanine). DP-IV was first identified as a membrane-bound protein. More recently a soluble form has been identified.
Initial interest in DP-IV focussed on its role in the activation of T lymphocytes. DP-IV is identical to the T cell protein CD26. It was proposed that inhibitors of DP-IV would be capable of modulating T cell responsiveness, and so could be developed as novel immunomodulators. It was further suggested that CD26 was a necessary co-receptor for HIV, and thus that DP-IV inhibitors could be useful in the treatment of AIDS.
Attention was given to the role of DP-IV outside the immune system. It was recognised that DP-IV has a key role in the degradation of several peptide hormones, including growth hormone releasing hormone (GHRH) and glucagon-like peptide-1 and -2 (GLP-1 and GLP-2). Since GLP-1 is known to have a potentiating effect on the action of insulin in the control of post-prandial blood glucose levels it is clear that DP-IV inhibitors might also be usefully employed in the treatment of type II diabetes and impaired glucose tolerance. At least two DP-IV inhibitors are currently undergoing clinical trials to explore this possibility.
Several groups have disclosed inhibitors of DP-IV. While some leads have been found from random screening programs, the majority of the work in this field has been directed towards the investigation of substrate analogues. Inhibitors of DP-IV that are substrate analogues are disclosed in, for example, US 5,462,928, US 5,543,396,
WO95/15309 (equivalent to US 5,939,560 and EP 0731789), W098/19998 (equivalent to US 6,011,155), W099/46272 and W099/61431.
More recently a number of proteins have been found that share some of the enzymatic properties of DP-IV. Some, such as FAP and DPP-8, have sequence homology with DP-IV, while others, such as QPP, have no such homology but nevertheless mimic the aminodipeptidase activity of DP-IV. The physiological function of these newer proteases is still being investigated. FAP has been implicated in invasive processes such as cancer metastasis and endometriosis, and QPP appears to be involved in immune-cell apoptosis. It is also possible that some of these proteases share a common function. This redundancy would allow continuing normal physiological function in the event of a failure in the expression or function of one of the proteases.
In order to further define the roles of these newer proteases it is important to have the tools to manipulate selectively each one or the whole class. Therefore there exists a need for specific and potent inhibitors of each of these proteases, and also for potent non-specific inhibitors of the class of post-proline cleaving aminodipeptidases.
SUMMARY OF THE INVENTION
We disclose herein a series of novel compounds that are inhibitors of one or more post-proline cleaving proteases, and specifically compounds according to general formula 1.
(Formula Removed)
In general formula 1, R1 is H or CN, X1 is O, S, CH2, CHF, CF2, CH(CH3), C(CH3)2 or CH(CN), and b is 1 or 2. G1 is H or a group according to the formula -CH2-X2-(CH2)a-G3 and G2 is H or a group according to the formula -CH2-(CH2)a-G3, provided that one of G1 and G2 is H and the other is not H. X2 is O, S or CH2, and a is 0,1 or 2, provided
that when a is 1 then X2 is CH2. G3 is a group according to one of general formulae 2-4.
(Formula Removed)
X3, X4 and X5 are either nitrogen N or CH, provided that at least two of X3, X4 and X5 are N. X6 is either O or NH. R2 is either H or alkyl. R3 is selected from H, CI, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2. R4, R5, R6, R7 and R8 are selected from H, Br, CI, F, CF3, alkyl, acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN. X7 is CH2, O, S or NH. R9 is either H or alkyl. R10, R11, R12, R13 and R14 are selected from H, Br, CI, F, CF3, alkyl. acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN. R15 and R16 are each independently H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl or CH2-L-R17, where L is a covalent bond, CH=CH, C≡C or -C6H4-, and R17 is H, alkyl or aryl, or R15 and R16 together are a group according to one of general formulae 5-7.
(Formula Removed)
R18 is H, alkyl, aryl, OH, O-alkyl, NH2, NH-alkyl or N(alkyl)2, and R19 is H, alkyl, aryl, F, CI, Br, CF3, OH, O-alkyl, NH2, NH-alkyl or N(alkyl)2. The integers d and e are 0,1,2 or 3 such that d+e is 3, 4 or 5, and f is 1, 2 or 3. When R15 and R16 are both H then X1 may not be S or CH2 if b is 1.
Preferred compositions are inhibitors of non-membrane associated post-proline cleaving proteases. The most preferred compositions are selective for non-membrane associated proteases (e.g. for example inhibitors of one or more of QPP, DPP-8 and/or DPP-9).
DETAILED DESCRIPTION OF THE INVENTION
In a first aspect, the present invention relates to a series of novel a-amino acyl derivatives of saturated nitrogen-containing heterocycles according to general formula 1.
(Formula Removed)
In general formula 1, the group R1 is either a hydrogen atom H or a nitrile group CN. The group X1 is selected from an oxygen atom O, a sulphur atom S, a methylene group CH2, a monofluoromethylene group CHF.a difluoromethylene group CF2, an ethylidene group CH(CH3), a 2-propylidene group C(CH3)2 and a cyanomethylene group CH(CN). The integer b is either 1 or 2, such that the nitrogen-containing ring has 5 or 6 members.
The group G1 is either H or a group according to the formula -CH2-X2-(CH2)a-G3 and the group G2 is either H or a group according to the formula -CH2-(CH2)a-G3, provided that one of G1 and G2 is H and the other is not H. The group X2 is selected from O, S and CH2. The integer a is 0,1 or 2, provided that when a is 1 then X2 is CH2.
The group G3 is selected from a group according to general formula 2, a group according to general formula 3 and a group according to general formula 4.
(Formula Removed)
In general formula 2, the groups X3, X4 and X5 are selected from nitrogen N and methine CH, provided that at least two of X3, X4 and X5 are nitrogen. Preferably X3, X4 and X5 are all nitrogen. The group X6 is selected from O and NH. R2 is selected from H and alkyl. R3 is selected from H, CI, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2. R4, R5, R6, R7 and R8 are independently selected from H, Br, CI, F, CF3, alkyl, acyl, OH, O-alkyi, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN.
In general formula 3, the group X7 is selected from CH2, O, S and NH. R9 is selected from H and alkyl. R10, R11, R12, R13 and R14 are independently selected from H, Br, CI, F, CF3, alkyl. acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN.
In general formula 4, R15 and R16 are each independently selected from H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl and CH2-L-R17, where L is selected from a covalent bond, CH=CH, C≡C and -C6H4- and R17 is selected from H, alkyl and aryl, or R15 and R16 together are a group selected from general, formula 5, general formula 6 and general formula 7.

(Formula Removed)
In these general formulae, the group R18 is selected from H, alkyl, aryl, OH, O-alkyl, NH2, NH-alkyI and N(alkyl)2. and the group R18 is selected from H, alkyl, aryl, F, CI, Br, CF3, OH, O-alkyl, NH2, NH-alkyI and N(alkyl)2. The integers d and e are selected from 0,1,2 and 3 such that d+e is 3,4 or 5, and the integer f is selected from 1, 2 and 3.
When R15 and R16 are both H then X1 may not be S or CH2 if b is 1.
The term alkyl, as used herein, denotes saturated hydrocarbon groups with between 1 and 10 carbon atoms, including straight-chain, branched and mono- and polycycloalkyi groups, such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, cyclopentyl, cyclohexylmethyl, 2-cyclohexyl-2-propyl, bicyclo[2.2.2]octyl and the like.
The term alkenyl, as used herein, denotes monounsaturated hydrocarbon groups with between 2 and 10 carbon atoms, including straight-chain, branched and mono- and polycycloalkenyl groups, such as vinyl, allyl, methallyl, cyclohex-3-enyl and the like.
The term aryl, as used herein, denotes monocyclic and fused bicyclic aromatic groups, including carbocyclic groups, such as pheny! and naphthyl, and heteroaryl groups with up to three heteroatoms selected from nitrogen, oxygen and sulphur, such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isothiazoiyl, pyridyl, pyrimidinyl, indolyl, quinolinyl and the like. Unless otherwise specified, aryl groups may optionally be substituted with up to three groups independently selected from alkyl, OH, O-alkyl, CI, F, Br, NH2, NH-alkyI, N(alkyl)2, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2, NO2 and CN.
The term aralkyl, as used herein, denotes alkyl groups that are substituted by, or fused to, one or more aryl groups, including benzyl, phenethyl, indanyl, fluorenyl and the like.
The term acyl, as used herein, denotes a group selected from H-CO, alkyl-CO, aryl-CO and aralkyl-CO, including formyl, acetyl, benzoyl, phenylacetyl and the like.
The term polyfluoroalkyl, as used herein, denotes an alkyl group wherein all the hydrogen atoms on one or more of the carbon atoms are replaced by fluorine atoms, including trifluoromethyl, 2,2,2-trifluoroethyl and the like.
In one preferred embodiment of the invention R1 is H.
In another preferred embodiment of the invention R1 is CN.
In another preferred embodiment of the invention X1 is CH2.
In another preferred embodiment of the invention X1is S.
In another preferred embodiment of the invention b is 1.
In another preferred embodiment of the invention b is 2.
In another preferred embodiment of the invention a is 0.
In another preferred embodiment of the invention a is 0 and X2 is CH2.
In another preferred embodiment of the invention a is 1.
In another preferred embodiment of the invention a is 1 and X2 is CH2.
In another preferred embodiment of the invention a is 2 and X2 is CH2.
In another preferred embodiment of the invention the compound is a compound according to general formula 8.
(Formula Removed)
In another preferred embodiment of the invention the compound is a compound according to general formula 9.
(Formula Removed)
In another preferred embodiment of the invention the compound is a compound according to general formula 10.
(Formula Removed)
In another preferred embodiment of the invention the compound is a compound according to general formula 11.
(Formula Removed)
In another preferred embodiment of the invention the compound is a compound according to general formula 12.
(Formula Removed)
In another preferred embodiment of the invention the compound is a compound according to general formula 13.
(Formula Removed)
It will be recognised that certain of the compounds within the scope of the present invention are capable of forming salts with suitable acids or bases. To the extent that such salts are pharmaceutically acceptable they are included within the scope of this invention
It Will further be recognised that certain of the compounds within the scope of the present invention are capable of existing as optical isomers, such as enantiomers and diastereomers. All such optical isomers and mixtures thereof, including but not limited to racemates, are included within the scope of the invention.
The compounds of the present invention are inhibitors of post-proiine cleaving proteases such as DPP-IV, QPP, FAP, DPP-8 (DPRP-1) and DPP-9 (DPRP-2). As such they may be useful in the treatment of diseases in which dysregulation of these enzymes or their endogenous substrates plays a role or the disease is ameliorated by inhibition of such enzymes. Accordingly, in further aspects, the present invention provides for the use of compounds according to the present invention in the preparation of pharmaceutical compositions, and for the use of such compositions a therapeutic agents.
Preferred compositions which are inhibitors for QPP may have G2=H, b = 1 or 2 and/or a = 0 or 1. Further preferred compositions having b=2 include G1 groups having a=0 or 1 and X2 is CH2. Further preferred compositions having b=2 have X1=CH2 or S, for example Example 38 of Table 2. Further preferred compositions having b=1 include G1 groups having a=0 or 1 and X2 is CH2.. Further preferred compositions having b=1 have X1= S or CH2or CF2, for example, Example 42 of Table 2.
The compounds of the present invention can be prepared by methods generally known in the art and illustrated in the following non-limiting examples.
EXAMPLES
EXAMPLE 1 (2S)-1-[N∞,N∞-{Dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitriIedihydrochloride
(Formula Removed)
A-(N∞-tert-Butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-
prolinamide
N∞-(tert-Butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-lysine (5g, 10.7mmol) was dissolved in CH2CI2 (100mL). The solution was cooled to 0°C, L-profinamide (1.78g, 11.7mmol) and PyBOP® (6.7g, 12.8mmol) were added, and the pH adjusted to pH9 with triethylamine. After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200mL). The solution was washed with 0.3M KHSO4 (2 x 50mL), sat. NaHCO3 (2 x 50mL), water (2 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as (N∞-(tert-butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-proIinamide (4.05g, 7.2mmol, 67%).
B. (2S)-1 -(Nα-(tert-Butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-
lysinyl)pyrrolidine-2-carbonitrile
(Nα-(tert-Butyloxycarbonyl)-N∞(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-prolin (3.95g, 7.02mmol) was dissolved in dry THF (100mL). The solution was cooled to 0°C, triethylamine (1.4g, 14mmol) was added followed by the slow addition of trifluoroacetic anhydride (2.97g, 14.1 mmol). The pH was adjusted to pH9 with triethylamine. After 30min the reaction mixture was diluted with ethyl acetate (100mL), washed with water (1 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography on silica gel (eluant: 60% pet ether, 40% ethyl acetate) to give a colourless oil identified as (2S)-1-(Nα-(tert-butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (3.3g, 6.11 mmol, 87%).
C. (2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile
(2S)-1-(Nα-(tert-Butyloxycarbonyl)-N∞-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-pyrrolidine-2-carbonitrile (3.1 g, 5.7mmol) was dissolved in THF (80mL). Diethylamine (20mL) was added. After 2h at room temperature the solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a colourless oil identified as (2S)-1-(Nα-(tert-butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (1.63g, 5.03mmoi, 89%).
D.(2S)-1-(Nα-(tert-Butyloxycarbonyl)-Nα,,N,-(dicinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile
(2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (100mg,
0.31 mmol) was dissolved in methanol (25mL). To this solution was added trans-cinnamaldehyde (170mg, 1.18mmol). After 30mins sodium triacetoxyborohydride (330mg, 1.56mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as (2S)-1-(N∞-(tert-butyloxycarbonyl)-N∞,N∞-(dicinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile (38mg, 0.068mmol, 11%). Further elution with 9% methanol, 90% chloroform and 1% acetic acid gave a colourless oil identified as (2S)-1-(N∞-(tert-butyloxycarbonyl)-N∞-(cinnamyl)-lysinyl)pyrrolidine-2-carbonitrile (32mg, 0.073mmol, 12%)
E. (2S)-1-[ N∞,N∞-(Dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride
(2S)-1-Nα-(tert-Butyloxycarbonyl)-N∞,N∞-(dicinnamyl)-L-lysinyl)pyrroIidine-2-carbonitrile (32mg, 0.057mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N∞,N∞'-(dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride (37mg, 0.053mmol, 93%).
[M+H]+ = 457.3
1H NMR (CD3OD): δ 1.35-1.55 (2H, m), 1.75-2.00 (2H, m), 2.05-2.23 (6H, m), 3.10-3.29 (4H, m), 3.61-3.68 (2H, m), 4.00-4.03 (4H, m), 4.20-4.30 (1H, m), 4.82-4.93 (1H, m), 6.34-6.39 (2H, m), 6.94 (2H, d, J = 5.8Hz), 7.31-7.37 (6H, m), 7.39-7.53 (4H, m) ppm.
EXAMPLE 2 (2S)-1-[N∞-(Cinnamyl)-L-lysinyl]pyrrolicline-2-carbonitriledihydrochloride
(Formula Removed)
A. (2S)-1 -[N∞Cinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride
(2S)-1-Nα-(tert-Butyloxycarbonyl)-N∞-(cinnamyl)-L-lysinyl)pyrrolidine-2-carbonytrile (32mg, 0.057mmol). was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N∞-(cinnamyl)-L-lysinyl]pyrroHdine-2-carbonitrile dihydrochloride (37mg, 0.053mmol, 93%).
[M+H]+ = 341.5
1H NMR (CD3OD): δ 1.29-1.55 (2H, m), 1.72-1.80 (2H, m), 1.90-2.11 (2H, m), 2.16-2.29 (6H, m), 3.02-3.09 (2H, m), 3.65-3.69 (2H, m), 3.78-3.82 (2H, m), 4.23-4.27 (1H, m), 4.81-4.82 (1H, m), 4.91-4.99 (1H, m), 6.21-6.32 (1H, m), 6.86 (1H, d, J=6.1Hz), 7.26-7.35 (3H, m), 7.37-7.40 (2H, m) ppm.
EXAMPLE 3
(2S)-1-[N∞,N∞-(Dicinnamyl)-L-ornithinyqpyrrolidine-2-carbonitrile dihydrochloride

(Formula Removed)
A.(2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-ornithyl)pyrrolidine-2-carbonitrile
(2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-ornithyl)pyrrolidine-2-carbonitrile was prepared by the method described for the lysine derivative in Example 1.
B.(2S)-1-(Nα-(tert-Butyloxycarbonyl)-N,Ndicinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile
(2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (200mg,
0.65mmo!) was dissolved in methanol (25mL). To this solution was added trans-
cinnamaldehyde (180mg, 1.25mmol). After 30mins sodium triacetoxyborohydride
(343mg, 1.63mmol) was added. After 18h at room temperature the solvent was
removed in vacuo and the residue was taken up in chloroform (70mL). This solution
was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and
evaporated in vacuo to give a yellow oil. The residue was purified by flash
chromatography (eluant 2% methanol, 98% chloroform) to give a colourless oil
identified as (2S)-1-(Nα-(tert-utyloxycarbonyl)-N,N-(dicinnamyl)-L-omithinyl)-
pyrrolidine-2-carbonitrile (77mg, 0.14mmol, 22%). Further elution with 9% methanol,
90% chloroform and 1% acetic acid gave a colourless oil identified as (2S)-1-(Nα-(tert-
butyloxycarbonyl)-N-cinnamyl)-L-omithinyl)pyrrolidine-2-carbonitrile (78mg,
0.18mmol, 28%).
C. (2S)-1 -[N,,N-(Dicinnamyl)-L-omithinyI]pyrrolidine-2-carbonitrile dihydrochloride
(2S)-1-(Nα-(tert-ButyloxycarbonyI)-N,N-(dicinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (67mg, 0.12mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N,N-(dicinnamyl)-L-omithinyl]pyrrolidine-2-carbonitrile dihydrochloride (82mg, 0.12mmol, 100%).
[M+H]+ = 443.3
1H NMR (CD3OD): δ 1.98-2.12 (4H, m), 2.22-2.29 (4H, m), 3.27-3.31 (4H, m), 3.62-3.67 (2H, m), 3.96 (4H, d, J=7.5Hz), 4.30-4.40 (1H, m), 4.80-4.83 (1H, m), 6.34-6.41 (2H, m), 6.96 (2H, d, J=15.6Hz), 7.31-7.39 (6H, m), 7.49-7.53 (4H, m) ppm.
EXAMPLE 4 (2S)-1-[N-(CinnamyI)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride
(Formula Removed)
A. (2S)-1-[N-(Cinnamyl)-L-ornithinyl3pyrrolidine-2-carbonitriledihydrochloride
(2S)-1-{Nα-(tert-Butyloxycarbonyl)-N-(cinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (71 mg, 0.17mmol). was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N-(cinnamyl)-L-ornithinyr]pyrrolidine-2-carbonitrile dihydrochtoride (91mg, 0.16mmol, 100%).
[M+H]+ = 327.5
1H NMR (CD3OD): δ 1.70-1.88 (2H, m), 1.97-2.01 (2H, m), 2.14-2.32 (4H, m), 3.08-3.13 (2H, m), 3.29-3.31 (3H, m), 3.68-3.71 (2H, m), 3.79-3.82 (2H, m), 4.29-4.31 (1H, m), 4.87-4.91 (1H, m), 6.29-6.31 (1H, m), 6.86 (1H, d, J=15.8Hz), 7.29-7.30 (3H, m), 7.44-7.48 (2H, m) ppm.
EXAMPLE 5 3-[N,N{Dicinnamyl)-L-lysinyl]thiazolidinedihydrochloride

(Formula Removed)
3-[Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-thiazolidine
Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-Iysine (2.73g, 6mmol) was dissolved in CH2CI2 /DMF (9:1, 100mL). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (1.53g, 10mmol), water-soluble carbodiimide (1.34g, 7mmol), thiazofidine (1.28g, 18mmol) and N-methylmorpholine (1.0g, 10mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 3-[Nα-(tert-butyloxycanbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyI]thiazolidine (2.55g, 4.85mmol, 81%).
B. 3-[Nα-(tert-Butyloxycarbonyl)-L-lysinyl]thiazolidine
3-[Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiazolidine (1.15g, 2.13mmol) was dissolved in acetonitrile (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-[Nα-(tert-butyloxycarbonyl)-L-lysinyl]thiazolidine (530mg, 1.67mmol, 78%).
C.3-(Nα-(tert-Butyloxycarbonyl)-N,N-{dicinnamyl)-L-lysinyl)thiazolidine
3-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)thiazolidine (200mg, 0.6mmol) was dissolved in methanol (25mL). To this solution was added trans-cinnamaldehyde (400mg, 3.0mmol). After 30mins sodium triacetoxyborohydride (534mg, 2.54mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20ml_) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as 3-(Nα-(tert-butyloxycarbonyl)-N,N-(di-cinnamyI)-L-lysinyl)thiazolidine (139mg, 0.25mmol, 40%).
D. 3-[N,NDicinnamyl)-L-lysinyl)thiazolidine dihydrochloride
3-(Nα-(tert-Butyloxycarbonyl)-N,Ndi-cinnamyl)-L-lysinyl)thiazolidine (139mg,
0.25mmol). was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N,Ndicinnamyl)-L-lysinyr]thiazolidine dihydrochloride (127mg, 0.24mmol, 96%).
[M+H]+ = 450.2
1H NMR (CD3OD): δ 1.49-1.55 (2H,m), 1.89-1.98 (4H, m), 3.01-3.30 (4H, m), 3.4-3.5 (4H, m), 3.7-3.9 (3H, m), 4.0-4.2 (3H, m), 4.2-4.8 (2H, br m), 6.38-6.44 (2H, m), 6.99-6.93 (2H, m), 7.34-7.37 (5H, m), 7.51-7.60 (4H, m) ppm.
EXAMPLE 6
3-[N,N-(Cinnamyl)-L-lysinyl]thiazolidine dihydrochloride
(Formula Removed)
A. 3-(Nα-(tert-Butyloxycarbonyl)-N,N-(cinnamyl)-L-lysinyl)thiazolidine 3-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)thiazoIidine (200mg, 0.6mmol) was dissolved in methanol (25mL). To this solution was added trans-cinnamaldehyde (400mg, 3.0mmol). After 30mins sodium triacetoxyborohydride (534mg, 2.54mmoI) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% triethylamine, 5% methanol, 94% chloroform) to give a colourless oil identified as 3-(Nα-(tert-butyloxycarbonyl)-N,N-(cinnamyl)-L-lysinyl)thiazolidine (215mg, 0.50mmol, 83%).
B. 3-[ NCinnamyl)-L-lysinyllthiazolidine dihydrochloride
3-(Nα-(tert-ButyIoxycarbonyl)-N,N-(cinnamyl)-L-lysinyl)thiazolidine (215mg,
0.5mmol). was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N,N(cinnamyl)-l.-lysinyr]thiazolidine dihydrochloride (160mg, 0.40mmol, 79%).
[M+H]+ = 334.4
1H NMR (CD3OD): δ 1.28-1.30 (1H, m), 1.51-1.53 (1H, m), 1.79-1.78 (1H, m), 1.93-1.98 (2H, m), 2.9-3.3 (5H, m), 3.6-3.8 (5H, m), 4.30-4.70 (5H, m), 6.2-6.3 (1H, m), 6.85-6.91 (1H, m), 7.1-7.7 (5H, m) ppm.
EXAMPLE 7
1 -[N-(Cyclohexylmethyl)-L-ornithinyl]pyrolidine dihydrochloride
(Formula Removed)
A. 1-[N-(Benzyloxycart)onyl)-Nα-(tert-butyloxycarbonyI)-L-ornithinyl]pyrrolidine
N-(Benzyloxycarbonyl)-Nα-tert-butyloxycarbonyl)-L-omithine (5.49g, 15mmol) was
dissolved in CH2CI2 /DMF (9:1, 100mL). To this solution at 0°C was added
1-hydroxybenzotriazole hydrate (3.37g, 22mmol), water-soluble carbodiimide (3.46g,
18mmol), pyrrolidine (1.28g, 18mmol) and N-methylmorpholine (2.0g, 20mmol). After
18h at 0°C to room temperature the solvent was removed in vacuo and the residue was
taken up in ethyl acetate (200mL). The solution was washed with 0.3M KHSO4 (2 x
50mL), sat. NaHCO3 (2 x 50mL), water (2 x 50mL) and brine (1 x 50mL), dried
(Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography
on silica gel (eluant: 90% ethyl acetate, 10% pet. ether) to give a colourless oil
identified as 1-[N-(benzyloxycarbonyl)-Nα-(tert-butyloxycarbonyl)-L-
omithinyl]pyrroIidine (5.15g, 12.3mmol, 82%).
B. 1 -[Nα-(tert-Butyloxycarbonyl)-L-ornithinyl]pyrrolidine 1-[Nα-(Benzyloxycarbonyl)-Nα-(tert-butyloxycarbonyl)-L-ornithinyl]pyrrolidine (2.15g, 5.13mmol) was dissolved in methanol (80mL). This solution was hydrogenated over 10% Pd/C (400mg). After 2h the catalyst was filtered off and washed with methanol (50mL). The combined filtrates were evaporated in vacuo to give an off white solid identified as 1-[Nα-(tert-butyloxycarbonyl)-L-omithinyl]pyrrolidine (1.35g, 4.74mmol, 94%).
C. 1-(Nα-(tert-Butyloxycarbonyl)-Nα-{cyclohexylmethyl)-L-ornithinyl)pyrrolidine
1-[Nα-tert-Butyloxycarbonyl)-L-omithinyl]pyrrolidine(100mg, 0.35mmol) was dissolved
in methanol (25mL). To this solution was added cyclohexanecarboxaldehyde (44mg,
0.39mmol). After 30mins sodium triacetoxyborohydride (148mg, 0.70mmol) was added.
After 18h at room temperature the solvent was removed in vacuo and the residue was
taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and
brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The
residue was purified by flash chromatography on silica gel (eluant: 1% triethylamine,
5% methanol, 94% chloroform) to give a colourless oil identified as 1-(N-(tert-
Butyloxycarbonyl)-N-(cyclohexylmethyl)-L-omithinyl)pyrrolidine (51 mg, 0.18mmol,
52%).
D. 1-[N-(Cyclohexylmethyl)-L-ornithinyl]pyrrolidine dihydrochloride
1 -(Nα-(tert-Butyloxycarbonyl)-N-{cyclohexylmethyl)-L-ornithinyl)pyrrolidine (215mg, 0.5mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(cyclohexylmethyl)-L-omithinyl]pyrrolidine dihydrochloride (160mg, 0.40mmol, 79%).
[M+H]+ = 282.3
1H NMR (CD3OD): δ 0.93-1.24 (3H, m), 1.66-1.81 (15H, m), 2.50-2.70 (2H, m), 2.71-
2.88 (2H, m), 3.2-3.48 (6H, m), 4.08 (1H, m), 8.35-8.38 (1H, m), 8.80-8.85 (1H, m)
ppm.
'EXAMPLE 8 3-[Ne-N,-(2-napthylmethyl)-L-lysinyl]thiazolidine dihydrochIoride
(Formula Removed)
A. Nα-(tert-Butyloxycarbonyl-Nα-benzyl-L-lysine methyl ester
Nα-(tert-ButyloxycarbonyI-L-lysine methyl ester (6.1 g, 22.2mmol) was dissolved in
methanol (100mL). To this solution was added benzaidehyde (1.9g, 17.5mmol). After
2 hours sodium triacetoxyborohydride (5.8g, 27.3mmol) was added. After 18h at room
temperature the solvent was removed in vacuo and the residue was taken up in
chloroform (200mL). This solution was washed with sat Na HCO3 (1 x 50mL}, water
(12 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give a
yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1%
acetic acid, 5% methanol, 94% chloroform) to give a colourless oil identified as Nα-{tert-
butyloxycarbonyl-N- benzyl-L-lysine methyl ester (5.2g, 14.2mmol, 82%).
B. Nα-tert-Butyloxycarbonyl-N-benzyl-N-methy|-L-Iysine methyl ester
Nα-tert-Butyloxycarbonyl-N-benzyl-L-lysine methyl ester (5.0g, 14.2mmol) was dissolved in methanol (100mL). To this solution was added formaldehyde (37% solution in water, 10mL). After 2 hours sodium triacetoxyborohydride (3.9g, 18.4mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (200mL). This solution was washed with sat. Na HCO3 (1 x 50mL), water (12 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give a. colourless oil identified as Nα-tert-butyloxycarbonyl- N-benzyl-N-methyl-L-lysine methyl ester (5.2g, 14.2mmol, 100%).
C. Nα-tert-ButyloxycarbonyI-N-methyl-L-lysine methyl ester
Nα-tert-Butyloxycarbonyl-N-benzyl-N,-methyl-L-lysine methyl ester (5.0g, 14.2mmol) was dissolved in methanol/water (9:1,100mL). To this solution was added ammonium formate (1.6, 19.3mmol) and 10% palladium on charcoal (2g). After 3 hours at 60 °C the catalyst was filtered off through celite and the residue washed with methanol (50mL). The combined filtrates were evaporated in vacuo and the residue was taken up in chloroform (200mL). This solution was washed with sat Na HCO3 (1 x 50mL),
water (12 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give a colourless oil identified as Nα-(tert-butyloxycarbonyl-N∞-methyl-L-lysine methyl ester (3.48g, 12.5mmol, 93%).
D. Nα-tert-Butyloxycarbonyl-N∞-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N∞-
methyl-L-lysine methyl ester
Nα-tert-Butyloxycarbonyl-N∞-methyl-L-lysine methyl ester (3.1g, 11.1mmol) was dissolved in dichloromethane (100mL). To this solution was added 1,1-dimethyl-2,2,2-trichloroethyl chloroformate (3.0g, 12.5mmol) and triethylamine (2.3g, 23mmol). After 18 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200mL). This solution was washed with 0.3M KHSO4 (1x 50mL),sat NaHCO3 (1 x 50mL), water (1 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil purified by flash chromatography on silica gel (eluant: 30% ethyl acetate, 70% pet. ether) to give colourless oil identified as Nα-(tert-butyloxycarbonyl-NO-(1,1 -dimethyl-2,2,2-trichloroethoxycarbonyl)-N-methyl-L-lysine methyl ester (3.28g, 6.98mmol, 63%).
E. Nα-tert-Butyioxycarbonyl-N-(1,1 -dimethyl-2,2,2-trichloroethoxycarbonyl)-N-
methyl-L-lysine
Nα-(tert-Butyloxycarbonyl-N-dirnethyl-2,2,2-trichloroethoxycarbonyl)-N-methyl-L-lysine methyl ester (3.1g, 6.6mmol) was dissolved in tetrahydrofuran (100mL). 1M Lithium hydroxide (7mL, 7.0mmol) was added. After 3 hours at room temperature the reaction mixture was diluted with ethyl acetate (150mL), washed with 1M HCI (1 x 50mL), water (1 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give colourless oil identified as Nα-(tert-butyloxycarbonyl-N-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N-methyl-L-lysine (2.94g, 6.45mmoI, 98%).
F. 3-(Nα-tert-Butyloxycarbonyl-N-(1,1 -dimethyl-2,2,2-trichloroethoxycarbonyl)-
N-methyl-L-lysinyl)thiazolidine
Nα-(tert-Butyloxycarbonyl-N-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N-methyl-L-lysine (700mg, 1.51 mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this solution at 0°C were added 1-hydroxybenzotriazoIe hydrate (410mg, 3.0mmol), water-soluble carbodiimide (250mg, 1.3mmol), thiazolidine (170mg, 1.9mmol) and N-methylmorpholine (1.0g, 10mmol). After 18h at 0°C to room temperature the solvent
was removed in vacuo and the residue was taken up in ethyl acetate (70mL). The solution was washed with 0.3M KHSO4 (1 x 25mL), sat. NaHCO3 (1 x 25mL), water (1 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether) to give a white solid identified as 3-(Nα-tert-butyloxycarbonyl-N∞-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-Ar-methvl-L-rysinyl)thiazolidine (758mg, 1.42mmol, 94%).
G. 3-{Nα-tert-Butyloxycarbonyl-N-methyl-L-lysinyl)thiazolidine 3-(Nα-tert-Butyloxycarbonyl-N∞-(1,1 -dimethyl-2,2,2-trichloroethoxycarbonyl)-N-methyl-L-lysinyl)thiazolidine (730mg, 1.36mmol) was dissolved in acetic acid (30mL). Zinc powder (200mg) was added. After stirring at room temperature for 18 hours the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). The solution was washed with sat. NaHCO3 (1 x 25mL), water (1 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo to give a colourless oil identified as 3-(Nα-tert-butyloxycarbonyi-N∞-methyl-L-lysinyl)thiazolidine (438mg, 1.32mmol, 97%).
H.3-[Nα-tert-Butyloxycarbonyl-N-methyl-N,-(2-napthylmethyl)-L-lysinyl]thiazolidine
3-{Nα-tert-Butyloxycarbonyl-N-methyl-L-lysinyl)thiazolidine (50mg, 0.15mmol) was
dissolved in 1,2-dichloroethane (20mL). To this solution was added 2-naphthaldehyde
(26mg, 0.17mmol). After 2 hours sodium triacetoxyborohydride (36mg, 0.17mmol) was
added. After 18h at room temperature the solvent was removed in vacuo and the
residue was taken up in chloroform (70mL). This solution was washed with water (2 x
20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow
oil. The residue was purified by flash chromatography on silica gel (eluant: 4%
methanol, 96% chloroform) to give a colourless oil identified as 3-[Na-tert-
butyloxycarbonyl-N,-methyl-N-(2-napthylmethyl)-L-lysinyl]thiazoIidine (51mg,
0.11mmol,72%).
1.3-[N-Wlethyl-N∞-(2-napthylmethyl)-L-lysinyl]thiazolidine dihydrochloride
3-[Nα-tert-Butyloxycarbonyl-N-methyl-N∞-(2-napthylmethyl)-L-lysinyl]thiazolidine (44mg, 0.093mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from
water to give a pale brown solid identified as 3-[N∞-methyl-N∞-(2-napthylmethy|)-L-
lysinyl]thiazolidine dihydrochloride (37mg, 0.083mmol, 89%).
[M+H]+ = 372.2
1H NMR (CD3OD): δ 1.50-1.53 (2H,m), 1.91-1.98 (4H,m), 2.82 (3H,s), 3.08-3.19
(4H,m), 3.36-3.75 (5H,m), 4.32-4.47 (2H,m), 4-60-4.71 (2H,m), 7.55-7.59 (2H,m), 7.65-
7.68 (1H,m), 7.90-8.00 (3H,m), 8.10-8.12 (1H,m) ppm.
EXAMPLE 9
3-[N-Methyl-N-(1-Napthylmetriyl)-L-omithyllthiazolidine dihydrochloride
(Formula Removed)
A.3-[N-(tert-Butyloxycarbonyl)-O∞-methyl-L-glutamyl]thiazoIicline
N-(tert-Butyloxycarbonyl)-O∞-methyl-L-glutamic acid (6.28g, 24mmol) was dissolved in CH2CI2/DMF (9:1, 100ml). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (5.5g, 36mmol), water-soluble carbodiimide (5.38g, 28mmol), thiazolidine (2.48g, 28mmol) and N-methylmorpholine (3.0g, 30mmol). The mixture was stirred for 18h at 0°C to room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150ml). The solution was washed with 0.3M KHSO4 (2 x 30ml), sat. NaHCO3 (2 x 30ml), water (2 x 30ml) and brine (1 x 30ml), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 70% ethyl acetate, 30% pet. ether 60-80) to give a brown oil identified as 3-[N-(tert-butyloxycarbonyi)-O∞,-methyl-L-glutamyr]thiazolidine (4.0g, 12mmol, 50%).
B. 3-[N,N-Di-(tert-butyloxycarbonyl)-O∞-methyl-L-glutamyl]thiazolidine
3-[N-(tert-Butyloxycarbonyl)-O∞-methyl-L-glutamyl]thiazolidine (3.2g, 9.6mmol) was dissolved in acetonitrile (20mL). Di-tert-butyl dicarbonate (3.14g, 14.4mmol) and 4-dimethylaminopyridine (235mg, 1.93mmol) were added. After 18 hours at room temperature further di-tert-butyl dicarbonate (3.14g, 14.4mmol) was added. After a further 3 days at room temperature the solvent was evaporated in vacuo the residue
was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet.
ether 60-80) to give a colourless oil identified as 3-[N,N-di-(tert-butyloxycarbonyl)-O-methyl-L-glutamyr]thiazolidine (2.0g, 4.63mmol, 48%).
C. 3-[N,N-Di-(tert-butyIoxycarbonyl)-L-glutamyl]thiazolidine
3-[N,N-di(tert-butyloxycarbonyl)-O-methyl-L-gutamyl]thiazolidine (950mg, 2.22mmol)
was dissolved in THF (50ml). 1M Lithium hydroxide (5.5ml, 5.5mmol) was added.
The mixture was stirred for 1 hour at room temperature then the solvent was removed
in vacuo and the residue was taken up in ethyl acetate (70ml). The solution was
washed with 0.3M KHSO4 (2 x 20ml), water (2 x 20ml) and brine (1 x 20ml), dried
(Na2SO4) and evaporated in vacuo to give a colourless oil identified as Z-[N,N-di-(tert-
butyloxycarbonyl)-L-glutamyl]thiazolidine (912mg, 2.2mmol, 98%).
D. 3-[2-(N,N-Di-(tert-butyloxycarbonyl)amino)-5-hydroxypentanoyl]thiazolidine
3-[N,N-Di-(tert-butyloxycarbonyl)-L-glutamyI]thiazolidine (912mg, 2.2mmol) was
dissolved in tetrahydrofuran (30 mL). This solution was cooled to -20 °C, N-
methylmorpholine (300mg, 2.96mmol) and isobutyi chloroformate (387mg, 2.83mmol)
were added. After 20 mins at -20 °C the reaction mixture was added to a solution of
sodium borohydride (182mg, 4.8mmol) in water (5mL) at 0°C. After 1 hour the reaction
mixture was diluted with ethyl acetate (150 mL). This solution was washed with water
(1 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a
colourless oil identified as 3-[2-(N,N-di-(tert-butyloxycarbonyl)amino)-5-hydroxy-
pentanoyl]thiazolidine (800mg, 2.0mmol, 92%).
E. 3-[2-(N,N-Di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine
3-[2-N,N-( (Di-tert-butyloxycarbonyI)amino)-5-hydroxypentanoyl]thiazolidine (800mg, 2.0mmol) was dissolved in dichloromethane (50 mL). Dess-Martin periodinane (933mg,2.2mmol) was added. After 1 hour at room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1 x 20ml) and brine (1 x 20ml), dried (Na2SO4) and evaporated in vacuo to give a colourless oil. Purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether 60-80) to give a colourless oil identified as 3-[2-(N,N-di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine (210mg, 0.52mmol, 26%).
F.3-[N,N-Di-(tert-butyloxycarbonyl-N-methyl-N-(1-napthylmethyl)-L-ornithyl]-thiazolidine
3-[N,N-Di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine was dissolved in
1,2-dichloroethane (20mL). To this solution was added N-methyl-1-
napthylmethylamine. After 2 hours sodium triacetoxyborohydride was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 3-[N,N-di-(tert-butyloxycarbonyI-N-methyl-N-(1-napthylmethyl)-L-omithyl]thia2olidine.
G. 3-[N-Methyl-N-(1-Napthylmethyl)-L-ornithyl]thiazolidine dihydrochloride
3-[N,N-Di-(tert-butyloxycartionyl-N,-methyl-N-(1-napthylmethyl)-L-omithyr|thiazolidine was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N-Me,N-(1-napthylmethyl)-L-omithyr|thiazolidine dihydrochloride.
EXAMPLE 10
3,3-Difluoro-l-[N-(2-methylbutyl)-L-lysinyl]pyrrolidine dihydrochloride
(Formula Removed)
A. 1 -(tert-ButyIoxycarbonyl)-3-pyrrolidone
(3R)-1-(tert-Butyloxycarbonyl)-3-hydroxypyrrolidine (980mg, 5.3mmol) was dissolved in CH2CI2 (40ml). Dess-Martin periodinane (2.5g, 5.8mmol) was added. The mixture was stirred for 3 hours at room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (300ml). The solution was washed with sat. NaHCO3, water and brine, dried (Na2SO4) and evaporated in vacuo to give a
colourless oil. The residue was purified by flash chromatography on silica gel (eluant: 20% ethyl acetate, 80% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyloxycarbonyl)-3-pyrrolidone (842mg, 4.6mmol, 87%).
B. 1 -(tert-Butyloxycarbonyl)-3,3-difluoropyrrolidine
1-(tert-Butyloxycarbonyl)-3-pyrrolidone (810mg, 4.4mmol) was dissolved in CH2CI2 (30ml). (Diethylamino)sulphur trifluoride (2.2g, 13.7mmol) was added to this solution at 0°C. The mixture was stirred for 18 hours at 0°C to room temperature then carefully poured into sat. NaHCO3 (100ml). The mixture was stirred for 15min then extracted with CH2CI2. The organic extract was washed with water and brine, dried (Na2SO4) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography (eluant: 10% ethyl acetate, 90% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyloxycarbonyl)-3,3-difluoropyrrolidine (580mg, 2.8mmol, 64%).
C. 3,3-Difluoropyrrolidine hydrochloride
1-(tert-Butyloxycarbonyl)-3,3-difluoropyrrolidine (540mg, 2.6mmol) was dissolved in 4M HCI/dioxan (30ml). The solution was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give an off white solid identified as 3,3-difluoropyrrolidine hydrochloride (370mg, 2.6mmol, 100%).
D. 1-[Nα-(tert-ButyIoxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyI]-3,3-
difluoropyrrolidine
Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysine (1.14g, 2.4mmol) was dissolved in CH2CI2 /DMF (9:1, 100ml). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (394mg, 2.9mmol), water-soluble carbodiimide (680mg, 3.4mmol), 3,3-difluoropyrrolidine hydrochloride (380mg, 2.43mmol) and N-methylmorpholine (400mg, 4mmol). The mixture was stirred for 18h at 0°C to room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200ml). The solution was washed with 0.3M KHSO4, sat. NaHCO3, water and brine, dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 65% ethyl acetate, 35% pet. ether 60-80) to give a white solid identified as 1-[Nα-(tert-butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-3,3-difIuoropyrrolidine (1.0g, 1.8mmol, 75%).
E. 1 -[Nα-tert-ButyIoxycarbonyl)4.-lysinyl]-3,3-difluoropyrrolidine
1-[Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-3,3-difluoro-pyrrolidine (1.01g, 1.8mmol) was dissolved in THF (20ml). Diethylamine (5ml) was added. The mixture was stirred for 3 hours at room temperature then the solvent was removed in vacuo and the residue was purified- by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pate yellow oil identified as 1-[Nα-(tert-butyloxycarbonyl)-L-lysinyl]-3.3-difluoropyrrolidine (598mg, 1.78mmol, 99%).
F. 1-[Nα-(tert-Butyloxycarbonyl)-N-(2-methylbutyl)-L-lysinyl]-3,3-difluoro-
pyrrolidine
1-[Nα-(tert-Butyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine was dissolved in 1,2-dichloroethane (20mL). To this solution was added 2-methylbutanal. After 2 hours sodium triacetoxyborohydride was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 1-[Nα-(tert-butyloxycarbonyl)-N-(2-methylbutyl)-L-lysinyl]-3,3-difluoropyrrolidine.
G. 3,3-Difluoro -1-[N-(2-methylbutyl)-L-lysinyl] pyrrolidine dihydrochloride
1-[N-(tert-Butyloxycarbonyl)-N-(2-methylbutyl)-L-lysinyl]-3,3-difluoropyrrolidine was dissolved in 4M HCI/dioxan (20ml). The mixture was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give a colourless oil identified as 3,3-difluoro-1-[N-(2-methyibutyl)-L-lysinyl]pyrrolidine dihydrochloride.
EXAMPLE 11
1-[N-(3-Cyclohexenylmethyl)-L-lysinyl]thiomorpholine dihydrochloride

(Formula Removed)
A. 3-[Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiomorpholine
Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysine (2.5g, 5.34mmol) was dissolved in CH2CI2 /DMF (9:1, 100mL). To this solution at 0°C were added 1-hydroxybenzotriazoIe hydrate (1.44g, 10.6mmol), water-soluble carbodiimide (1.35g, 6.5mmol), thiomorpholine (710mg, 6.9mmol) and N-methylmorpholine (800mg, 8mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white
solid identified as 3-[Nα-(tert-butyloxycarbonyl)-Nfluorenylmethyloxycarbonyl)-L-iysinyl]thiomorpholine (2.70g, 4.88mmol, 91%).
B. 3-[Nα-(tert-Butyloxycarbonyl)-L-lysinyl]thiomorpholine
3-[Nα-(tert-Butyloxycarbonyl)-N-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiomorpholine (2.6g, 4.7mmol) was dissolved in tetrahydrofuran (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-[Nα-tert-butyloxycarbonyl)-L-lysinyl]thiomorpholine (1.2g, 3.637mmol, 77%).
C. 3-[Nα-(tert-Butyloxycarbonyl)-N-(3-cyclohexenylmethyl)-L-lysinyl]-
thiomorpholine
3-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)thiomorpholine (150mg, 0.45mmol) was
dissolved in methanol (25mL). To this solution was added 3-
cyclohexenecarboxaldehyde (400mg, 0.45mmol). After 30mins sodium
triacetoxyborohydride (150mg, 0.71 mmol) was added. After 18h at room temperature
the solvent was removed in vacuo and the residue was taken up in chloroform (70ml_).
This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4)
and evaporated in vacuo to give a yellow oil. The residue was purified by flash
chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to
give a colourless oil identified as 3-(Nα-(tert-butyloxycarbonyl)-Nα'-(3-
cyclohexenylmethyl)-L-lysinyl)thiomorphoIine (66mg, 0.12mmol, 26%).
D. 1 -[N-(3-Cyclohexenylmethyl)-L-lysinyI]thiomorpholine dihydrochloride
3-(Nα-(tert-Butyloxycarbonyl)-N(3-cyclohexenylmethyl)-L-Iysinyl)thiomorpholine (66mg, 0.12mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(3-cydohexenylmethyl)-L-lysinyl]thiomorpholine dihydrochloride (62mg, 0.12mmol, 100%).
[M+H]+ = 326.2
EXAMPLE 12
(2S)-1-[N-{2-(3'-trifluoromethylanilino)pyridyl-3-carbonyl)-L-omithyl]thiazolidine
dihydrochloride
(Formula Removed)
A. 3-[Nα-tert-Butyloxycarbonyl-N-(1,1 -dimethyl-2,2,2-trichloroethoxycarbonyl)-L-ornithyl]thiazolidine
Nα-(tert-Butyloxycarbonyl-N-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-omithine (2.5g, 5.9mmol) was dissolved in CH2CI2 /DMF (9:1, 30mL). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (1.6g, 11.9mmol), water-soluble carbodiimide (1.4g, 7.6mmol), thiazolidine (650mg, 7.3mmol) and N-methylmorpholine (2.0g, 20mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70ml_). The solution was washed with 0.3M KHSO4 (1 x 25mL), sat. NaHCO3 (1 x 25mL), water (1 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether) to
give a colourless oil identified as 3-[Nα-tert-butyloxycarbonyl-N-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-omithyllthiazolidine (758mg, 1.42mmol, 94%).
B. 3-{Nα-tert-Butyloxycarbonyl- L-omithinyl)thiazolidine
3-[Nα-tert-Butyloxycarbonyl-N-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-
ornithyl]thiazolidine (130mg, 0.26mmol) was dissolved in acetic acid (30mL). Zinc
powder (100mg) was added. After stirring at room temperature for 18 hours the solvent
was removed in vacuo and the residue was taken up in chloroform (70mL). The
solution was washed with sat NaHCO3 (1 x 25ml), water (1 x 25mL) and brine (1 x
25mL), dried (Na2SO4) and evaporated in vacuo to give a colourless oil identified as 3-
(Nα-tert-butyloxycarbonyl-L-omithinyl)thiazolidine (80mg, 0.26mmol, 100%).
C. 3-[Nα-tert-Butyloxycarbonyl-N-(2-(3'-trifluoromethylanilino)pyridyl-3-
carbonyl)-L-ornrthinyl]thiazoIidine
3-(Nα-tert-Butyloxycarbonyl-L-omithinyl)thiazolidine (80mg, 0.26mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this solution at 0°C was added 1-hydroxybenzotriazole hydrate (80mg, 0.6mmol), water-soluble carbodiimide (65mg, 0.32mmol), niflumic acid (82mg, 0.29mmol) and N-methylmorpholine (100mg, 1.0mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70mL). The solution was washed with 0.3M KHSO4 (1 x 20mL), sat. NaHCO3 (1 x 20mL), water (1 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a yellow oil identified as 3-[Na-tert-butyloxycarbonyl-N-(2-(3'-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithinyl]-thiazolidine (60mg, 0.12mmol, 45%).
D. (2S)-1-[N-(2-(3'-Trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithyl]-
thiazolidine dihydrochloride
3-[Nα-tert-Butyloxycarbonyl-N-(2-(3'-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithinyl]thiazolidine (54mg, 0.10mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as (2S)-1-[N-(2-(3-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithyl]thiazolidine dihydrochloride (47mg, 0.10mmol, 100%).
[M+H]+ = 468.0
1H NMR (CD3OD): δ1.77-1.82 (2H, m), 1.84-2.00 (2H, m), 3.03-3.15 (4H, m), 3.41-3.51 (2H, m), 3.65-3.71 (2H, m), 3.80-3.87 (1H, m), 4.46-4.49 (2H, m), 4.65-4.72 (2H, m), 7.06-7.11 (1H, m), 7.61-7.11 (3H, m), 7.95 (1H, s), 8.09 (1H, d, J=4.7Hz), 8.49 (1H, d, J= 4.2Hz) ppm.
EXAMPLE 13
3,3-Difluoro-1-[N-{2-(3'-chIoroanilino)pyridyl-3-carbonyl)-L-omithyl]pyrrolidine
dihydrochloride
(Formula Removed)
A. 1-[Nα-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine
1-[Nα-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine was prepared as described for the lysine derivative in Example 9.
B. 3-Chloroanilinonicotinic acid
3-Chloroaniline was dissolved in xylene. 2-Aminonicotinic acid was added. The reaction mixture was heated at 150 °C for 18 hours after which time the reaction mixture was diluted with ethyl acetate giving an off-white solid identified as 3-chloroanilinonicotinic acid.
C. 3,3-Difluoro-INα-tert-butyloxycarbonyl-N-(2-{3,-chloroanilino)pyridyl-3-
carbonyl)-L-ornithinyl]pyrrolidine
1-[Nα-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine was dissolved in CH2CI2 /DMF (9:1, 20mL). To this solution at 0°C was added 1-hydroxybenzotriazole hydrate, water-soluble carbodiimide, 3-chloroanilinonicotinic acid and N-methylmorpholine.
After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70mL). The solution was washed with 0.3M KHSO4 (1 x 20mL), sat. NaHCO3 (1 x 20mL), water (1 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl, acetate, 25% pet. ether) to give a yellow oil identified as 3,3-difluoro-[Nα-tert-butyloxycarbonyl-N-(2-(3,-chloroanilino)pyridyl-3-carbonyl)]-L-omithinyl)pyrroIidine.
D. 3,3-Difluoro-1 -[N-(2-(3'-chloroanilino)pyridyl-3-carbonyl)-L-omithyl]pyrrolidinedihydrochloride
3,3-Difluoro-[Nα-tert-butyloxycarbonyl-N-(2-(3'-chloroanilino)pyridyl-3-carbonyl)]-L-ornithinyl)pyrrolidine was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3,3-difluoro-1-[N-(2-(3'-chloroanilino)pyridyl-3-carbonyl)-L-omithyl]pyrrolidine dihydrochloride.
EXAMPLE 14
3-[N-6-Chloro-4-(2,,5'-dichloroanilino)-1,3,5-triazinyI)-L-lysinyI]thiazoIidine
dihydrochloride
(Formula Removed)
A. 4,6-Dichloro-2-{2',5'-dichloroanilino)-1,3,5-triazine
Cyanuric chloride (1.844g, 10mmol) was dissolved in acetonitrile (20mL). The solution was cooled to -20 °C. A solution of 2,5-dichloroaniline (1.62g, 10mmol) and triethylamine (1.0g, 10mmol) was slowly added. After 1 hour at -20 °C the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150mL). The
solution was washed with water (1 x 50mL) and brine (1 x 50mL), dried (Na;>SO4) and evaporated in vacuo. The residue was recrystallised from ethyl acetate/ hexane to give an off white solid identified as 4,6-dichloro-2-(2'>5'-dichloroaniiino)-1,3I5-tria2ine (1.86mg, 6.0mmol, 60%).
B. 3-[Nα-tert-Butyloxycarbonyl-N-6-chloro-4-(2,,5'-dichloroanilino)-1,3,5-triazinyI)4_-lysinyl]thiazotidine
3-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)thiazolidine (800mg, 2.58mmol) was dissolved in dichloromethane (30mL). To this solution was added 4,6-dichloro-2-(2',5'-dichloroanilino)-1,3,5-triazine (810mg, 2.6mmol) and triethylamine (300mg, 3.0mmol). After 2 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150mL). This solution was washed with water (2 x 30mL) and brine (1 x 30mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 3-[Nα-tert-butyloxycarbonyl-N-6-chloro-4-(2',5'-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine (1.33g, 2.23mmol, 86%).
C.3-[N-6-Chloro-4-(2',5'-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride
3-[Nα-tert-ButyloxycarbonyI-N-6-chloro-4-(2,5,-dichloroanilino)-1,3,5-triazinyl)-L-
lysinyl]thiazolidine (59mg, 0.10mmol) was dissolved in 4M HCI/dioxan (20mL). After
1h at room temperature the solvent was removed in vacuo. The residue was
lyophilised from water to give a white solid identified as 3-[N,-6-chloro-4-(2',5'-
dichloroanilno)-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride (55mg, 0.098mmo!,
98%).
[M+H]+ = 492.2, 494.4
1H NMR (CD3OD): δ1.46-1.51 (2H,m), 1.65-1.67 (2H,m), 1.80-1.96 (2H,m), 3.05-3.14
(2H,m), 3.38-3.42 (2H,m), 3.55-3.75 (4H,m), 4.31-4.36 (2H,m0, 4.40-4.52 (1H,m), 4.63-
4.95 (2H,m), 7.15-7.18 (1H,m), 7.40-7.45 (1H,m), 8.15-8.25 (1H,m) ppm.
EXAMPLE 15
3-[N-4-2',5'-Dichloroanilino)-6-hydroxy-1,3,5-tria2fnyl)-L-lysinyl]thiazolidine bis(trifluoroacetate)
A.3-[N(2',5'-Dichloroanilino)-6-hydroxy-1,3,5-triazinyl)-L-lysinyl]thiazolidine bis(trifluoroacetate)
3-[Nα-tert-Butyloxycarbonyl-N-6-chloro-4-(2',5-dichloroanilino)-1,3,5-triazinyI)]-L-
ornithinyl)thiazolidine (54mg, 0.09mmol) was dissolved in trifluoroacetic acid (20mL)
and water (2mL). After 2 hours at 70 °C the solvent was removed in vacuo. The
residue was lyophilised from water to give a white solid identified as 3-[N-4-(2',5'-
dichioroanilino)-6-hydroxy-1,3,5-triazinyl)-L-lysinyl]thiazolidine bis(trifluoroacetate)
(63mg, 0.089mmol, 97%).
[M+H]+ = 472.1,474.2
1H NMR (CD3OD): δ1.42-1.47 (2H,m), 1.62-1.67 (2H,m). 1.82-1.89 (2H,m), 3.04-3.16
(4H,m), 3.70-3.75 (2H,m), 3.84-3.91 (1H,m), 4.25-4.32 (2H,m), 4.45-4.54 (2H,m), 4.64-
4.70 (2H,m), 7.05-7.15 (1H,m), 7.34-7.38 (1H,m), 7.49-7.55 (1H,m), 7.80-7.92 (1H,m)
ppm.
i
EXAMPLE 16
3-[Nα-4-(2',5'-Dichloroanilino)-6-methylamino-1,3,5-triazinyl)-L-lysinyl]thiazofidine
dihydrochioride
(Formula Removed)
A.3-[Nα-tert-Butyloxycarbonyl-N-4-(2,'5'-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine
3-[Nα-tert-Buty!oxycarbonyl-N-3-chloro-5-(2',5'-dichloroanilino)-2,4,6-triazinyl)]-L-omithinyl)thiazolidine (120mg, 0.20mmol) was dissolved in 1M dimethylamine in tetrahydrofuran (25mL). After 18 hours at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether) to give a white solid identified as 3-[Nα-tert-butyloxycarbonyl-N.5'-dichloroanilino)-6-dimethylamino-1.3.5-triazinyl)-L-lysinyl]thiazolidine (110mg, 0.18mmol, 90%).
B. 3-[ N-4-(2',5'-Dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]-thiazolidine dihydrochioride
3-INα-tert-Butyloxycarbonyl-N∞-4-(2',5'-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine (110mg, 0.18mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-[N-4-(2',5'-dichloroanilino)-6-dimethylamino-1,3,5-triazinyI)-L-lysinyl]thiazolidine dihydrochioride (105mg, 0.18mmol, 100%).
[M+H]+ = 499.1, 501.1
1H NMR (CD3OD): δ1.52-1.55 (2H,m), 1.69-1.71 (2H,m), 1.90-1.98 (2H,m), 3.13-3.22 (8Htm), 3.48-3.62 (2H,m), 3.65-3.69 (4H,m). 4.37-4.39 (2H,m), 4.46-4.49 (1H,m), 4.57-4.77 (2H,m), 7.20-7.22 (1H,m), 7.45-7.50 (1H,m), 8.09-8.12 (1H,m) ppm.
The following compounds were prepared by analogous methods.
TABLE

(Table Removed)
EXAMPLE 1277
1-[2-(S)-Amino-4-(cycIohexylmethylamino)butanoyl]thiomorpholine dihydrochlonde

A. 1 -[2-(S)-N-(tert-Butyloxycarbonyl)amino-4-(9-
fluorenylmethyloxycarbonylamino)-butanoyl]thiomorpholine
1-[2-(S)-N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-
butanoic acid (1.0g, 2.27mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this
solution at 0°C were added 1-hydroxybenzotriazole hydrate (461 mg, 3.41 mmol), water-
soluble carbodiimide (521 mg, 2.72mmol), thiomorpholine (281 mg, 2.72mmol) and
triethylamine (340mg, 3.4mmol). After 18h at 0°C to room temperature the solvent
was removed In vacuo and the residue was taken up in ethyl acetate (100mL). The
solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x
25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue
was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet.
ether) to give a white solid identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)amino- 4-(9-
fluorenylmethyloxycarbonylamino)-butanoyl]thiomorpholine (516mg, 0.98mmol, 43%).
B. 1 -[2-(S)-N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine
1-[2-(S)-N-(tert-Butyloxycarbonyl)amino- 4-(9-fluorenylmethyloxycarbonylamino)-
butanoyl thiomorpholine (500mg, 0.95mmol) was dissolved in tetrahydrofuran (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1 -[2-(S)-N-(tert-butyIoxycarbonyl)-4-amino)-butanoyl]thiomorpholine (162mg, 0.54mmol, 56%).
C. 1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]
thiomorpholine
1-[2-(S)-N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine (41 mg, 0.135mmol) was dissolved in dichloroethane (1 OmL). To this solution was added cyclohexanecarboxaldehyde (15mg, 0.135mmol). After 30mins sodium triacetoxyborohydride (32mg, 0.15mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl] thiomorpholine (25mg, 0.063mmol, 47%).
D. 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine
dihydrochloride
1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-
(cycIohexylmethylamino)butanoyl]thiomorpholine (25mg, 0.063mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine dihydrochloride (23mg, 0.063mmol, 100%).
[M+H]+ = 300.3
EXAMPLE 1278
1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine dihydrochloride

(Formula Removed)
A. 1-[2-{S)-N-{tert-Butyloxycarbonyl)-amino-4-((quinolin-2-
ylmethyl)amino)butanoyl thiomorpholine
1-[2-(S)-N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine (41 mg, 0.135mmo!) was dissolved in 1,2-dichloroethane (10mL). To this solution was added 2-quinolinecarboxaldehyde (32mg, 0.15mmol). After 30mms sodium triacetoxyborohydride (36mg, 0.17mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl thiomorpholine (32mg, 0.072mmol, 53%).
B. l-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine
dihydrochloride
1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl] thiomorpholine (12mg, 0.027mmol) was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine dihydrochloride (11.3mg, 0.027mmol, 100%).
[M+H]+ = 345.3
EXAMPLE 1279 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]piperidine dihydrochloride
(Formula Removed)
A. 1 -[2-(S)-N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl] piperidine
1-[2-(S)-N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoic acid (947mg, 2.154mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this
solution at 0°C were added 1-hydroxybenzotriazole hydrate (436mg, 3.2mmol), water-soluble carbodiimide (495g, 2.58mmol), piperidine (220g, 2.58mmol) and triethylamine (320mg, 3.2mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet ether) to give a white solid identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)amino- 4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]piperidine (556mg, 1.1mmol, 51%).
B. 1-[2-(S)-N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]piperidine
1-[2-(S)-N-(tert-Butyloxycarbonyl)amino- 4-(9-fluorenylmethyloxycarbonylamino)-
butanoyl] piperidine (540g, 1.1mmol) was dissolved in tetrahydrofuran (20mL).
Diethylamine (5mL) was added. After 90min at room temperature the solvent was
removed in vacuo and the residue was purified by flash chromatography on silica gel
(eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil
identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)-4-amino)-butanoyl] piperidine (171 mg,
0.6mmol, 57%).
C. 1-[2-(S)-N-(tert-ButyIoxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]
piperidine
1-[2-(S)-N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl] piperidine (43mg, 0.15mmol) was dissolved in 1,2-dichloroethane (20mL). To this solution was added cyclohexanecarboxaldehyde (17mg, 0.15mmol). After 30mins sodium triacetoxyborohydride (36mg, 0.17mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine (38mg, 0.1mmol, 66%).
D. 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl] piperidine
dihydrochloride
1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine (38mg, O.lmmol) was dissolved in 4M HCl/dioxan (2mL). After 1h at room
temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-(cyclohexylmethylamino)butanoyl] piperidine dihydrochloride (33mg, 0.093mmol, 93%).
[M+H]+ = 282.3
EXAMPLE 1280
1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine dihydrochloride
(Formula Removed)
A. 1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-((quinoIin-2-
ylmethyl)amino)butanoyl] piperidine
1-[2-(S)-N-(tert-Butyloxycarbonyl)-4-arnino)-butanoyl] piperidine (24mg, 0.15mmol) was dissolved in 1,2-dichloroethane (25mL). To this solution was added 2-quinolinecarboxaldehyde (24mg, 0.15mmol). After 30mins sodium triacetoxyborohydride (36mg, 0.17mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (etuant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-{S)-N-(tert-butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl] piperidine (35mg, 0.082mmol, 55%).
B. l-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)batanoyl] piperidine
dihydrochloride
1-[2-(S)-N-(tert-Butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl] piperidine (35mg, 0.082mmol) was dissolved in 4M HCI/dioxan (2mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised
from water to give a white solid identified as 1-[2-(S)-amino-4-((quinolin-2-yImethyl)amino)butanoyI] piperidine dihydrochloride (26mg, 0.065mmol, 79%).
[M+H]+ = 327.3
EXAMPLE 1281
3-Fluoro-1-[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine dihydrochloride
A. 1 -(tert-Butyloxycarbonyl)-3-fluoropyrrolidine
N-(tert-ButyIoxycarbonyl)-3-hydroxypyrrolidine (21 .Og, 10.7mmol) was dissolved in CH2CI2 (30ml). (Diethylamino)sulphur trifluoride (1.72g, 10.7mmol) was added to this solution at -78 °C. The mixture was stirred for 18 hours at -78 °C to room temperature then the reaction mixture was carefully poured into sat. NaHCO3 (100ml) and stirred for 15min and extracted with CH2CI2. The organic extract was washed with water and brine, dried (Na2SO4) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography (eluant: 28% ethyl acetate, 72% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyIoxycarbonyl)-3-fluoropyrrolidine (1.14g, 5.34mmol, 50%).
B 3-Fluoropyrrolidine hydrochloride
1-(tert-Butyloxycarbonyl)-3-fluoropyrrolidine (1.14g, 5.34mmol) was dissolved in 4M HCI/dioxan (30ml). The mixture was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give an off-white solid identified as 3-fluoropyrrolidine hydrochloride (640mg, 5.2mmol, 95%).
C. 3-Fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl] pyrrolidine
1-[2-(S)-N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-
butanoic acid (950mg, 2.15mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this
solution at 0°C were added 1-hydroxybenzotriazole hydrate (395mg, 2.6mmol), water-soluble carbodiimide (572mg, 3.0mmol), 3-fluoropyrrolidine hydrochloride (270g, 2.15mmol) and triethylamine (320mg, 3.2mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 3-fluoro1-[2-(S)-N-(tert-butyloxycarbonyl)amino- 4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]pyrrolidine (808mg, 1.58mmol,73%).
D. 3-Fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]pyrrolidine
3-Fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)amino- 4-(9-
fluorenylmethyloxycarbonylamino)-butanoyl] pyrrolidine (800mg, 1.58mmo!) was dissolved in tetrahydrofuran (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)-4-amino)-butanoyl] pyrrolidine (316mg, 1.04mmol, 66%).
E. 3-Fluoro-1 -[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-
(cyclohexenylmethylamino)butanoyl] pyrrolidine
3-Fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)-4-amino)-butanoyl] pyrrolidine (150mg, 0.52mmol) was dissolved in methanol (20mL). To this solution was added 3-cyclohexenecarboxaldehyde (63mg, 0.57mmol). After 30mins sodium triacetoxyborohydride (220mg, 1.04mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 3-fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine (176mg, 0.46mmol, 77%).
F. 3-Fluoro-1 -[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl] pyrrolidine dihydrochloride
3-Fluoro-1-[2-(S)-N-(tert-butyloxycarbonyl)-amino-4-
(cyclohexenylmethylamirio)butanoyl]pyrrolidine (176mg, 0.46mmol) was dissolved in 4M HCI/dioxan (2mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-fluoro-1 -[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl] pyrrolidine dihydrochloride (140mg, 0.39mmol, 963%).
[M+H]+ = 284.3
EXAMPLE 1282
l-[2-(S)-Amino-4-(N-methyl-N-(2-methylbengyl)amino)butanoyl]piperidine dihydrochloride
(Formula Removed)
A. N-(tert-Butyloxycarbonyl)-L-homoserine lactone
L-Homoserine lactone 1.76g, 12.8mmol) was dissolved in DMF (30 mL). This solution was cooled to 0 °C, triethylamine (1.41, 14.1 mmol) di-tert-butyl dicarbonate(3.35g, 15.35 mmol) was added. After 18 hours at room temperature the solvent was evaporated in vacuo, the residue was taken up in dichloromethane (200 mL). This solution was washed with 1M KHSO4 (2 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo to give a white solid, recrystallised from EtOAc/petether to give a white solid identified as N-(tert-butyloxycarbonyl)-L-homoserine lactone (2.25mg, 11.2mmol, 87%).
B. 1-[2-(S)-(N-(tert-Butyloxycarbonyl)amino)-4-hydroxybutanoyl]piperidine
N-(tert-Butyloxycarbonyl)-L-homoserine lactone (100mg, 0.5mmol) was dissolved in tetrahydrofuran (30 mL). Piperidine (42mg, 0.5mmol) was added. After 72 hours at
room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil identified as 1-[2-(S)-(N-(tert-butyloxycarbonyl)amino)-4-hydroxybutanoyrjpiperidine (142mg, 0.5mmol, 100%).
C. 1-[2-(S)-(N-(tert-Butyloxycart)onyI)amino)-4-oxobutanoyl] piperidine
1-[2-(S)-(N-(tert-Butyloxycarbonyi)amino)-4-hydroxybutanoyl] piperidine (142mg, 0.5mmol) was dissolved in dichloromethane (50 mL). Dess-Martin periodinane (232mg, 0.5mmol) was added. After 1 hour at room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1 x 20ml) and brine (1 x 20ml), dried (Na2SO4) and evaporated in vacuo to give a colourless oil. Purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether 60-80) to give a colourless oil identified as 1-[2-(S)-(N-(tert-butyloxycarbonyl)amino)-4-oxobutanoyl] piperidine (40mg, 0.14mmol, 27%).
D. 1-[2-(S)-(N -{tert-butyloxycarbonyl)amino-4-(N-methyl-N-(2-
methylbenzyl)amino) butanoyl]piperidine
1-[2-(S)-(N-(tert-Butyloxycarbonyl)amino)-4-oxobutanoyl] piperidine (40mg, 14mmol) was dissolved in methanol (20mL). To this solution was added N-methyl-2-methylbenzylamine (19mg, 0.14mmol). After 2 hours sodium triacetoxyborohydride (64mg, 0.3mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 1-[2-{S)-(N -(tert-butyloxycarbonyIi)amino-4-(N-methyl-N-(2-methylbenzyl)amino) butanoyl] piperidine (36mg, 0.09mmol, 64%).
E. 1 -[2-(S)-Amino-4-(N-methyl-N-(2-methylbenzyl)amino)butanoyl] piperidine
dihydrochloride
1-[2-(S)-(N-(tert-Butyloxycarbonyl)amino-4-(N-methyl-N-(2-methylbenzyl)amino) butanoyl] piperidine (36mg, 0.09mmol)was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 1-[2-(S)-amino-4-(N-
methyl-N-(2-methylbenzyI)amino)butanoyl] piperidine dihydrochloride (43mg, 0.09mmol, 100%)
EXAMPLE 1283 l-[N-(2"-(Cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine dihydrochloride
(Formula Removed)
A. 1 -[N-2'-(tert-Butyloxycarbonyl)-N-(2"-(9-fluorenylmethyIoxycarbonyl
aminoethyl)-glycinyl]thiomorpholine
N-2'-(tert-Butyloxycarbonyl)-N-(2',-(9-fIuorenylmethyloxycarbonyl aminoethyl)-glycine (2.5g, 5.7mmol) was dissolved in CH2CI2 /DMF (9:1,100mL). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (833mg, 6.3mmol), water-soluble carbodiimide (974mg, 6.3mmol), thiomorpholine (617mg, 6.0mmol) and N-methylmorpholine (800mg, 8mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 1-[N-2',-(tert-butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]thiornorpholine (2.7g, 5.1mmoI, 90%).
B. 1 -[N-2'-(tert-Butyloxycarbonyl)-(2"-aminoethyl)-glycinyl] thiomorpholine
1-[N-2'-(tert-ButyloxycarbonyI)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-
glycinyl]thiomorpholine (2.7g, 5.1mmol) was dissolved in tetrahydrofuran (20mL). Diethyiamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[N-2'-(tert-butyloxycarbonyl)-(2"-aminoethyl)-glycinyl] thiomorpholine (1.44g, 4.7mmol, 92%).
C. 1-[2'-N-(tert-Butyloxycarbonyl N-(cyclohexylmethylaminoethyl)-glycinyl]
thiomorpholine
1-[N-2'-(tert-Butyloxycarbonyl)-(2"-aminoethyl)-glycinyll thiomorpholine (100mg, 0.3mmol) was dissolved in methanol (25mL). To this solution was added cyclohexanecarboxaldehyde (34mg, 0.3mmol), After 30mins sodium triacetoxyborohydride (126mg, 0.6mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2"-N-(tert-Butyloxycarbonyl N-(2"-(cyclohexylmethylaminoethyl)-glycinyl] thiomorpholine (33mg, 0.08mmol, 27%).
D. l-[N-(2"-(Cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine
dihydrochloride
1-[2'-N-(tert-Butyloxycarbonyl-N-(2'-(cyclohexylmethylaminoethyl)-glycinyl] thiomorpholine (33mg, 0.081 mmol) was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(2"-(cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine dihydrochloride (31 mg, 0.08mmol, 100%).
[M+H]+ = 300.3
EXAMPLE 1284 l-[N-(2"-((Quinolin-2-ylmethyl)aminoethyl)glycinyl)]pyrrolidine dihydrochloride
(Formula Removed)
A. 1-[N-2'-(tert-Butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyI
aminoethyl)-glycinyl]piperidine
N-2,-(tert-Butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycine (2.5g, 5.7mmol) was dissolved in CH2CI2 /DMF (9:1, 10OmL). To this solution at 0°C were added 1-hydroxybenzotriazole hydrate (1.5g, 11.1mmol), water-soluble carbodiimide (1.3g, 6.8mmoI), piperidine (484mg, 5.69mmol) and N-methylmorpholine (800mg, 8mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25mL), sat. NaHCO3 (2 x 25mL), water (2 x 25rnL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet ether) to give a white solid identified as 1-[N-2,-(tert-butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]piperidine (2.8g, 5.5mmol, 96%).
B. 1 -[N-2*-{tert-Butyloxycarbonyl)-(2"-aminoethyI)-glycinyl] piperidine
1-[N-2'-(tert-Butyloxycarbonyl)-N-(2"(9-fluorenylmetnyloxycarbonyl aminoethyl)-
glycinyl]piperidine (2.8g, 5.5mmol) was dissolved in tetrahydrofuran (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[N-2'-(tert-butyloxycarbonyl)-(2"-aminoethyl)-glycinyI] piperidine (1.4g, 4.9mmol, 89%).
C. 1-[2'-N-(tert-ButyIoxycarbonyl N-(2"-((quinolin-2-ylmethyl)aminoethyl)-
glycinyl] piperidine
1-[N-2'-(tert-Butyloxycarbonyl)-(2"-aminoethyl)-glycinyrj piperidine was dissolved in methanol (25mL). To this solution was added 2-quinolinecarboxaldehyde. After 30mins sodium triacetoxyborohydride was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid,9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-N-(tert-butyloxycarbonyl N-(2"-((quinolin-2-ylmethyl)aminoethyl)-glycinyl] piperidine.
D. l-[N-(2"-((Quinolin-2-ylmethyl)aminoethyl)glycinyl)]piperidine dihydrochloride
1-[2'-N-(tert-Butyloxycarbonyl-N-(2"-((quinolin-2-ylmethyl)aminoethyl)-glycinyl] piperidine was dissolved in 4M HCl/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-{2-(quinoIin-2-ylmethyl)aminoethyl)glycinyl)]piperidine dihydrochloride.
EXAMPLE 1285 l-[N,N-(2",2"-((Dicinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride
(Formula Removed)
A. 1-[2'-N-(tert-Butyloxycarbonyl N,N-(2",2"-((dicinnamyl)aminoethyl)-glycinyl] thiomorpholine
(2S)-1-(Nα-(tert-Butyloxycarbonyl)-L-lysinyl)-pyrrolidine-2-carbonitrile (250mg,
0.83mmol) was dissolved in dichloroethane (25mL). To this solution was added trans-cinnamaldehyde (108mg, 0.83mmol). After 30mins sodium triacetoxyborohydride (350mg, 1. 6mmol) was added. After 18h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70mL). This solution was washed with water (2 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as 1-[2'-N-(tert-butyIoxycarbonyl N,N-(2',2"-((dicinnamyl)aminoethyl)-glycinyl] thiomorpholine. Further elution with 9% methanol, 90% chloroform and 1% acetic acid gave a colourless oil identified as 1-[2-N-(tert-butyloxycarbonyl N,-(2"-((cinnamyl)aminoethyl)-glycinyl] thiomorpholine (180mg, 0.43mmol, 52%)
B. 1-[N,N-(2",2"-((Dicinnamyl)aminoethyl)glycinyl)]thiomorpholine
dihydrochloride
1-[2'-N-(tert-Butyloxycarbonyl N,N-(2",2,,-((dicinnamyl)aminoethyl)-gIycinyl]
thiomorpholine was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature
the solvent was removed in vacuo. The residue was lyophilised from water to give a
white solid identified as 1-[N,N-(2",2"-((dicinnamyl)aminoethyl)glycinyl)]thiomorpholine
dihydrochloride.
EXAMPLE 1286 l-[N-(2"-((Cinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride
(Formula Removed)
A. 1 -[N-(2"-((Cinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride
1-[2'-N-(tert-Butyloxycarbonyl N-(2"-((cinnamyl)aminoethyI)-glycinyl] thiomorpholine (180mg, 0.43mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(2"-((cinnamyl)aminoethyl)glycinyl)lthiomorphoIine dihydrochloride (168mg, 0.43mmol, 100%).
[M+H]+ = 320.3
EXAMPLE 1287
3.3-Difluoro-1-[N-2''-(3'-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)gIycinyl)]pyrrolidine dihydrochloride
(Formula Removed)
A.3,3-Difluoro-1-[N-2'-(tert-butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl] pyrrolidine
N-2'-(tert-Butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycine (1.0g, 2.27mmol) was dissolved in CH2CI2 /DMF (9:1,100mL). To this solution at 0°C were added 1-hydroxybenzotriazoIe hydrate (620mg, 4.6mmol), water-soluble carbodiimide (560mg, 2.8mmol), 3,3-difluoropyrrolidine hydrochloride (360mg, 2.5mmol) and N-methylmorpholine (800mg, 8mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100mL). The solution was washed with 0.3M KHSO4 (2 x 25ml_), sat. NaHCO3 (2 x 25mL), water (2 x 25mL) and brine (1 x 25mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 3,3-difluoro-1-[N-2"-(tert-butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl] pyrrolidine (934g, 1.7mmol, 77%).
B.3,3-Difluoro-1-[N-2'-(tert-butyIoxycarbonyl)aminoethyI)-glycinyl] pyrrolidine 3,3-Difluoro-1-[N-2'-(tert-butyloxycarbonyl)-N-(2"-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl] pyrrolidine (890g, 1.68mmol) was dissolved in tetrahydrofuran (20mL). Diethylamine (5mL) was added. After 90min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3,3-difluoro-1-[N-2'-(tert-butyloxycarbonyl)aminoethyl)-glycinyl] pyrrolidine (470mg, 1.5mmol, 91%).
C. 3,3-Difluoro-1-[ N-2'-(tert-butyloxycarbonyl)-N-2"-(3'-trifluoromethylanilino)pyridyl-3-carbonylaminoethyl)glycinyl)]pyrrolidine
3,3-Difluoro-1-[N-2'-(tert-butyloxycarbonyl)aminoethyl)-glycinyl] pyrrolidine (50mg,
0.16mmol) was dissolved in CH2CI2 /DMF (9:1, 20mL). To this solution at 0°C was
added 1-hydroxybenzotriazole hydrate (46mg, 0.34mmol), water-soluble carbodiimide (40mg, 0.2mmol), niflumic acid (49mg, 0.17mmol) and N-methylmorpholine (40mg, 0.4mmol). After 18h at 0°C to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70mL). The solution was washed with 0.3M KHSO4 (1 x 20mL), sat. NaHCO3 (1 x 20mL), water (1 x 20mL) and brine (1 x 20mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a yellow oil identified as 3.3-difluoro-1-[N-2'(tert-butyloxycarbonyl)-N-2''-(3'-trifiuoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine (63mg, 0.11mmol,67%).
D. 3,3-Difluoro-1 -[N-2"-(3'-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl) glycinyl)]pyrrolidine dihydrochloride
3,3-Difluoro-1-[N-2'-(tert-butyloxycarbonyl)-N-2"-(3'-trifluoromethylanilino)pyriyl-3 carbonyl aminoethyl)glycinyl)]pyrrolidine (55mg, 0.10mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pate brown solid identified as 3,3-difluoro-1-[N-2"-(3'-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine dihydrochloride (52mg, 0.10mmol, 100%).
[M+H]+ = 472.3
EXAMPLE 1288
3,3-Difluoro-[N-2"-(6-Chloro-4-(4'-fluoroanilino)-1,3,5-triazinyl)aminoethyl) glycinyl)]thiomorphoIine dihydrochloride
(Formula Removed)
A. 4,6-Dichloro-2-(4'-fluoroanilino)-1,3,5-triazine
Cyanuric chloride (1.844g, 10mmol) was dissolved in acetonitrile (20mL). The solution was cooled to -20 °C. A solution of 4-fluoroaniiine (1.1g, 10mmol) and triethylamine (1.0g, 10mmol) was slowly added. After 1 hour at -20 °C the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150mL). The solution was washed with water (1 x 50mL) and brine (1 x 50mL), dried (Na2SO4) and evaporated in vacuo. The residue was recrystallised from ethyl acetate/ hexane to give an off white solid identified as 4,6-dichloro-2-(4'-fluoroanilino)-1,3,5-triazine 1.7g, 6.0mmol, 60%).
B. 1-[ N-2-(tert-butyloxycarbonyl)-N-2"- (6-Chloro-4-(4'-fluoroanilino)-1,3,5-
triazinyl aminoethyl)glycinyl)] thiomorpholine
1-[N-2'-(tert-butyloxycarbonyl)aminoethyl)-glycinyl] thiomorpholine (100mg, 0.3mmol) was dissolved in dichloromethane (30mL). To this solution was added 4,6-dichloro-2-(4'-fluoroanilino)-1,3,5-triazine (90mg, 0.3mmol) and triethylamine (50mg, 0.5mmol). After 2 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150mL). This solution was washed with water (2 x 30mL) and brine (1 x 30mL), dried (Na2SO4) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 1-[N-2'-(tert-butyloxycarbonyl)-N-2"- (6-chloro-4-(4'-fluoroanilino)-1,3,5-triazinyl aminoethyl)glycinyl)] thiomorpholine (20mg, 0.032mmol, 11%).
C. 1 -[N-2"-(6-Chloro-4-(4'-fluoroanilino)-1,3,5-triazinyl)aminoethyl) glycinyl)]
thiomorpholine dihydrochloride
1 -[N-2'-(tert-butyloxycarbonyl)-N-2 (6-chloro-4-(4'-fluoroanilino)-1 ,3,5-triazinyl
aminoethyl)glycinyl)] thiomorpholine (18.8mg, 0.03mmol) was dissolved in 4M HCI/dioxan (20mL). After 1h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-2"-(6-Chloro-4-(4'-fluoroanilino)-1,3,5-triazinyl)aminoethyl) glycinyl)] thiomorpholine dihydrochloride (18mg, 0.03mmol, 100%). [M+H]+ = 526.4
TABLE 9
(Table Removed)

CLAIMS
1 A compound according to general formula 1, or a pharmaceutically acceptable salt thereof,
(Formula Removed)
wherein:
either G1 is -CH2-X2-(CH2)a-G3 and G2 is H, or
G2 is -CH2-(CH2)a-G3 and G1 is H;
G3 is selected from a group according to general formula 2, a group according
to general formula 3, and a group according to general formula 4;
(Formula Removed)
a is 0,1 or 2;
b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
X2 is selected from CH2, O and S, provided that if a is 1 then X2 is CH2;
X3, X4 and X5 are selected from N and CH, provided that at least two of X3, X4
and X5 are N;
X6 is selected from O and NH;
X7 is selected from CH2, O, S and NH;
R1 is selected from H and CN;
R2 is selected from H and alkyl;
R3 is selected from H, CI, OH, O-alkyl, NH2l NH-alkyl and N(alkyl)2;
R4, R5, R6, R7 and R8 are independently selected from H, Br, CI, F, CF3, alkyl,
acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl,
CONH2, CONH-alkyl, CON(alkyl)2 and CN;.
R9 is selected from H and akyl;
R10, R11, R12, R13 and R14 are independently selected from H, Br, CI, F, CF3,
alkyl, acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2l NH-acyl, CO2H, COz-
alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN;
R15 and R16 are independently selected from H, alkyl, alkenyl, polyfluoroalkyl,
aralkyl, aryl and -CH2-L-R17, or R15 and R16 together form a group according
to general formula 5, general formula 6 or general formula 7;
(Formula Removed)
R17 is selected from H, alkyl and aryl;
R18 is selected from H, alkyl, aryl, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2;
R19 is selected from H, alkyl, aryl, F, CI, Br, CF3, OH, O-alkyl, NH2, NH-alkyl
and N(alkyl)2;
L is selected from a covalent bond, CH=CH, CsC and -C6H4-;
d and e are selected from 0,1,2 and 3 such that d+e is 3,4 or 5; and
f is selected from 1, 2 and 3;
provided that when R15 and R16 are both H and b is 1 then X1 is not S or CH2.
2 A compound according to general formula 8, or a pharmaceutically acceptable salt thereof,
(Formula Removed)
wherein:
a is 0,1 or 2;
b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
X2 is selected from CH2, O and S, provided that if a is 1 then X2 is CH2;
X3, X4 and Xs are selected from N and CH, provided that at least two of X3, X4
and X5 are N;
X6 is selected from O and NH;
R1 is selected from H and CN;
R2 is selected from H and alkyl;
R3 is selected from H, CI, OH, O-alkyI, NH2, NH-alkyl and N(alkyl)2;
R4, R5, R6, R7 and R8 are independently selected from H, Br, CI, F, CF3, alkyl,
acyl, OH, O-alkyl. NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl,
CONH2, CONH-alkyl, CON(alkyl)2 and CN.
3 A compound according to Claim 2 wherein R1 is H.
4 A compound according to Claim 2 wherein R1 is CN.
5 A compound according to any of Claims 2 to 4 wherein X1 is CH2.
6 A compound according to any of Claims 2 to 4 wherein X1 is S.
7 A compound according to any of Claims 2 to 6 wherein b is 1.
8 A compound according to any of Claims 2 to 6 wherein b is 2.
9 A compound according to any of Claims 2 to 8 wherein a is 1.
10 A compound according to any of Claims 2 to 8 wherein a is 2 and X2 is CH2.
11 A compound according to any of Claims 2 to 10 wherein X3, X4 and X5 are all
N.
12 A compound according to general formula 9, or a pharmaceutically
acceptable salt thereof,
(Formula Removed)
wherein:
a is 1 or 2; b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O; X3, X4 and X5 are selected from N and CH, provided that at least two of X3, X4 and X5 are N;
X6 is selected from O and NH; R1 is selected from H and CN; R2 is selected from H and alkyl;
R3 is selected from H, CI, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2; R4, R5, R6, R7 and R8 are independently selected from H, Br, CI, F, CF3, alkyl,
acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN.
13 A compound according to Claim 12 wherein R1 is H.
14 A compound according to Claim 12 wherein R1 is CN.
15 A compound according to any of Claims 12 to 14 wherein X1 is CH2.
16 A compound according to any of Claims 12 to 14 wherein X1 is S.
17 A compound according to any of Claims 12 to 16 wherein b is 1.
18 A compound according to any of Claims 12 to 16 wherein b is 2.
19 A compound according to any of Claims 12 to 18 wherein a is 1.
20 A compound according to any of Claims 12 to 19 wherein X3, X4 and X5 are all
N.
21 A compound according to general formula 10, or a pharmaceutically
acceptable salt thereof,
(Formula Removed)
wherein:
a is 0,1 or 2;
b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
X2 is selected from CH2, O and S, provided that if a is 1 then X2 is CH2;
X7 is selected from O, S, CH2 and NH;
R1 is selected from H and CN;
R9 is selected from H and alkyl;
R10, R11, R12, R13 and R14 are independently selected from H, Br, CI, F, CF3, .
alkyl; acyl, OH, O-alkyl, NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, CO2H, CO2-
alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN is selected from H, CI, OH,
O-alkyl, NH2, NH-alkyl and N(alkyl)2.
22 A compound according to Claim 21 wherein R1 is H.
23 A compound according to Claim 21 wherein R1 is CN.
24 A compound according to any of Claims 21 to 23 wherein X1 is CH2.
25 A compound according to any of Claims 21 to 23 wherein X1 is S.
26 A compound according to any of Claims 21 to 25 wherein b is 1.
27 A compound according to any of Claims 21 to 25 wherein b is 2.
28 A compound according to any of Claims 21 to 27 wherein a is 1.
29 A compound according to any of Claims 21 to 27 wherein a is 2 and X2 is
CH2.
30 A compound according to general formula 11, or a pharmaceutically
acceptable salt thereof,
(Formula Removed)
wherein:
a is 1 or 2;
b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
X7 is selected from O, S, CH2 and NH;
R1 is selected from H and CN;
R9 is selected from H and alkyl;
R10, R11, R12, R13 and R14 are independently selected from H, Br, CI, F, CF3,
alkyl, acyl, OH, O-alkyl. NH2, NH-alkyl, N(alkyl)2, NO2, NH-acyl, COzH, COr
alkyl, CONH2, CONH-alkyl, CON(alkyl)2 and CN is selected from H, CI, OH,
O-alkyl, NH2, NH-alkyl and N(alkyl)2.
31 A compound according to Claim 30 wherein R1 is H.
32 A compound according to Claim 30 wherein R1 is CN.
33 A compound according to any of Claims 30 to 32 wherein X1 is CH2.
34 A compound according to any of Claims 30 to 32 wherein X1 is S.
35 A compound according to any of Claims 30 to 34 wherein b is 1.
36 A compound according to any of Claims 30 to 34 wherein b is 2.
37 A compound according to any of Claims 30 to 36 wherein a is 1.
38 A compound according to general formula 12, or a pharmaceutically acceptable salt thereof,
(Formula Removed)
wherein:
a is 0,1 or 2;
b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
X2 is selected from CH2, O and S, provided that if a is 1 then X2 is CH2;
R1 is selected from H and CN;
R15 and R16 are each independently selected from H, alkyl, alkenyl,
polyfluoroalkyl, aralkyl, aryl and CH2-L-R17;
or R15 and R16 together are a group according to general formula 5, a group
according to general formula 6 or a group according to general formula 7;
(Formula Removed)
R17 is selected from H, alkyl and aryl;
R18 is selected from H, alkyl, aryl, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2; R19 is selected from H, alkyl, aryl, F, CI, Br, CF3, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2;
L is selected from a covalent bond, CH=CH, C=C and -C6H4-;
d and e are selected from 0,1, 2 and 3 such that d+e is 3,4 or 5; and
f is selected from 1,2 and 3;
provided that when R15 and R16 are both H and b is 1 then X1 is not S or CH2.
39 A compound according to Claim 38 wherein R1 is H.
40 A compound according to Claim 38 wherein R1 is CN.
41 A compound according to any of Claims 38 to 40 wherein X1 is CH2.
42 A compound according to any of Claims 38 to 40 wherein X1 is S.
43 A compound according to any of Claims 38 to 42 wherein b is 1.
44 A compound according to any of Claims 38 to 42 wherein b is 2.
45 A compound according to any of Claims 38 to 44 wherein a is 1.
46 A compound according to any of Claims 38 to 44 wherein a is 2 and X2 is
CH2.
47 A compound according to general formula 13, or a pharmaceutically
acceptable salt thereof,
(Formula Removed)
wherein:
a is 1 or 2; b is 1 or 2;
X1 is selected from CH2, S, CF2, CHF, CH(CH3), C(CH3)2, CH(CN) and O;
R1 is selected from H and CN;
R15 and R16 are each independently selected from H, alkyl, alkenyl,
polyfluoroalkyl, aralkyl, aryl and CH2-L-R17;
or R15 and R16 together are a group according to general formula 5, a group
according to general formula 6 or a group according to general formula 7;
(Formula Removed)
R17 is selected from H, alkyl and aryl;
R18 is selected from H, alkyl, aryl, OH, O-alkyl, NH2, NH-alkyl and N(alkyl)2;
R19 is selected from H, alkyl, aryl, F, CI, Br, CF3, OH, O-alkyl, NH2, NH-alkyl
and N(alkyl)2;
L is selected from a covalent bond, CH=CH, C≡C and -C6H4-;
d and e are selected from 0,1, 2 and 3 such that d+e is 3,4 or 5; and
f is selected from 1, 2 and 3.
48 A compound according to Claim 47 wherein R1 is H.
49 A compound according to Claim 47 wherein R1 is CN.
50 A compound according to any of Claims 47 to 49 wherein X1 is CH2.
51 A compound according to any of Claims 47 to 49 wherein X1 is S.
52 A compound according to any of Claims 47 to 51 wherein b is 1.
53 A compound according to any of Claims 47 to 51 wherein b is 2.
54 A compound according to any of Claims 47 to 53 wherein a is 1.
55 A pharmaceutical composition comprising a compound according to any of
Claims 1 to 54.
56 A use for a compound according to any of Claims 1 to 54, which is as a
component in the preparation of a pharmaceutical composition.
57 A method of treatment of disease in a human or animal subject, comprising a
step of administering to the subject a therapeutically active amount of a compound according to any of Claims 1 to 54
58 A method of treatment according to claim 57 where the disease is caused by
dysregulation of a post-proline cleaving proteases or their endogenous substrates.
59 A method of treatment according to claim 57 where the disease is
ameliorated by inhibition of a post-proline cleaving proteases.
60 A method of treatment according to claim 57 where the disease is caused by
dysregulation of a post-proline cleaving proteases or its endogenous substrates which is an intracellular protease.
61 A composition according to claim 1 or 38 with the proviso that when X1 = S; b
= 1; R1 = H; G2 = H; G1 is-CH2-X2-(CH2)a-G3; a = 1, X2 = CH2; G3 = NR15R16; and one of R15, R16 = H, the other of R15, R16 is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
62 A composition according to claim 1, 38, 47 or 61 with the proviso that when
b=1, R1 is H and X1 is S; G1 = H; G2 is -CH2-(CH2)a-G3; a = 1; G3 is NR15R16 and one of R15 and R16 is H the other of R15, R16 is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
63 A composition according to claim 1, 38, 47, 61 or 62 with the proviso that
when b=1, R1 is CN and X1 is CH2; G1 = H; G2 is -CHr(CH2)a-G3; a = 1; G3 is NR15R16 and one of R15 and R16 is H, the other of R1S, R16 is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
94 A composition according to claim 1, 38,47, 61, 62 or 63 with the proviso that when G2 = H; G1 = -CH2-X2-(CH2)a-G3; X2 is CH2; a = 1; G3 = NR15R16 and R1S = R16 = H; b is not 2 when X1 is O or CH2, and b is not 1 when X1 is CH2.
65 A method of treatment according to claim 57 in which the disease is caused
by dysregulation of a non-membrane associated post-proline cleaving proteases such as QPP, DPP-8 and DPP-9 enzymes or their endogenous substrates.
66 A method of treatment according to claim 57 in which the disease is
ameliorated by inhibition of a non-membrane associated post-proline cleaving proteases such as QPP, DPP-8 and DPP-9 enzymes or their endogenous substrates.
67 A method according to claim 65 or 66 in which the compound is a selective
inhibitor of non-membrane associated post-proline cleaving proteases.
68. A compound according to general formula 1, or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
69. A compound according to general formula 8 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
70. A compound according to general formula 9 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
71. A compound according to general formula 10 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
72. A compound according to general formula 11 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
73. A compound according to general formula 12 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
74. A compound according to general formula 13 or a pharmaceutically acceptable salt thereof substantially as herein described with reference to the foregoing examples.
75. A pharmaceutical composition comprising a compound substantially as herein described with reference to the foregoing examples.
76. A use for a compound substantially as herein described with reference to the foregoing examples.
77. A method of treatment of disease in a human or animal subject substantially as herein described with reference to the foregoing examples.